The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon

FASEB Journal

Volumn 24, Issue 5, 2010, Pages 1479-1488

  Fernández De Marco, María Del Mar ^a   Alejo, Alí ^b   Hudson, Paul ^c   Damon, Inger K ^c   Alcami, Antonio ^a,d  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cytokine; Immune modulation; Infection; Smallpox; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; TYPE 1 INTERFERON BINDING PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; INTERFERON; VIRUS PROTEIN; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONKEYPOX VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; SMALLPOX VIRUS; SURFACE PLASMON RESONANCE; VIRUS VIRULENCE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MONKEYPOX; PATHOGENICITY; SMALLPOX; TUMOR CELL LINE;

ANIMALIA; MONKEYPOX VIRUS; VARIOLA; VARIOLA VIRUS;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOMODULATION; INTERFERON TYPE I; MONKEYPOX; MONKEYPOX VIRUS; SMALLPOX; VARIOLA VIRUS; VIRAL PROTEINS; VIRAL VACCINES; VIRULENCE FACTORS;

EID: 77952298465     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-144733     Document Type: Article

References (45)

1. De Souza Trindade, G., Drumond, B. P., Guedes, M. I., Leite, J. A., Mota, B. E., Campos, M. A., da Fonseca, F. G., Nogueira, M. L., Lobato, Z. I., Bonjardim, C. A., Ferreira, P. C., and Kroon, E. G. (2007) Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals. J. Clin. Microbiol. 45, 1370-1372
2. Smith, G. L., and McFadden, G. (2002) Smallpox: anything to declare? Nat. Rev. 2, 521-527
3. Di Giulio, D. B., and Eckburg, P. B. (2004) Human monkeypox: an emerging zoonosis. Lancet 4, 15-25
4. Nalca, A., Rimoin, A. W., Bavari, S., and Whitehouse, C. A. (2005) Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin. Infect. Dis. 41, 1765-1771
5. Alcami, A. (2003) Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. 3, 36-50
6. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A., and McFadden, G. (2003) Poxviruses and immune evasion. Annu. Rev. Immunol. 21, 377-423
7. Stanford, M. M., McFadden, G., Karupiah, G., and Chaudhri, G. (2007) Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. 85, 93-102
8. Randall, R. E., and Goodbourn, S. (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47
9. Samuel, C. E. (1991) Antiviral actions of interferon. Interferonregulated cellular proteins and their surprisingly selective antiviral activities. Virology 183, 1-11
10. Biron, C. A. (1998) Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10, 383-390
11. Ank, N., Iversen, M. B., Bartholdy, C., Staeheli, P., Hartmann, R., Jensen, U. B., Dagnaes-Hansen, F., Thomsen, A. R., Chen, Z., Haugen, H., Klucher, K., and Paludan, S. R. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLRinduced antiviral activity. J. Immunol. 180, 2474-2485
12. Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L., and Hartmann, R. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81, 7749-7758
13. Takaoka, A., and Yanai, H. (2006) Interferon signalling network in innate defence. Cell. Microbiol. 8, 907-922
14. Davies, M. V., Elroy-Stein, O., Jagus, R., Moss, B., and Kaufman, R. J. (1992) The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J. Virol. 66, 1943-1950
15. Chang, H. W., Watson, J. C., and Jacobs, B. L. (1992) The E3L gene of vaccinia virus encodes an inhibitor of the interferoninduced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 89, 4825-4829
16. Smith, V. P., and Alcami, A. (2002) Inhibition of interferons by ectromelia virus. J. Virol. 76, 1124-1134
17. Alcami, A., Symons, J. A., and Smith, G. L. (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74, 11230-11239
18. Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A., and Buller, R. M. (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270, 15974-15978
19. Symons, J. A., Alcami, A., and Smith, G. L. (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551-560
20. Alcami, A., and Smith, G. L. (1996) Soluble interferon-gamma receptors encoded by poxviruses. Comp. Immunol. Microbiol. Infect. Dis. 19, 305-317
21. Upton, C., Mossman, K., and McFadden, G. (1992) Encoding of a homolog of the IFN-gamma receptor by myxoma virus. Science 258, 1369-1372 (Pubitemid 23007791)
22. Smith, G. L., and Chan, Y. S. (1991) Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72(Pt 3), 511-518
23. Alcami, A., and Smith, G. L. (1992) A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167
24. Verardi, P. H., Jones, L. A., Aziz, F. H., Ahmad, S., and Yilma, T. D. (2001) Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity. J. Virol. 75, 11-18
25. Xu, R. H., Cohen, M., Tang, Y., Lazear, E., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H., and Sigal, L. J. (2008) The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J. Exp. Med. 205, 981-992
26. Shchelkunov, S. N., Totmenin, A. V., Babkin, I. V., Safronov, P. F., Ryazankina, O. I., Petrov, N. A., Gutorov, V. V., Uvarova, E. A., Mikheev, M. V., Sisler, J. R., Esposito, J. J., Jahrling, P. B., Moss, B., and Sandakhchiev, L. S. (2001) Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 509, 66-70
27. Dunlop, L. R., Oehlberg, K. A., Reid, J. J., Avci, D., and Rosengard, A. M. (2003) Variola virus immune evasion proteins. Microbes Infect. 5, 1049-1056
28. Weaver, J. R., and Isaacs, S. N. (2008) Monkeypox virus and insights into its immunomodulatory proteins. Immunol. Rev. 225, 96-113
29. Rubins, K. H., Hensley, L. E., Jahrling, P. B., Whitney, A. R., Geisbert, T. W., Huggins, J. W., Owen, A., Leduc, J. W., Brown, P. O., and Relman, D. A. (2004) The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc. Natl. Acad. Sci. U. S. A. 101, 15190-15195
30. Rubins, K. H., Hensley, L. E., Bell, G. W., Wang, C., Lefkowitz, E. J., Brown, P. O., and Relman, D. A. (2008) Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS ONE 3, e2628
31. Huang, J., Smirnov, S. V., Lewis-Antes, A., Balan, M., Li, W., Tang, S., Silke, G. V., Putz, M. M., Smith, G. L., and Kotenko, S. V. (2007) Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc. Natl. Acad. Sci. U. S. A. 104, 9822-9827
32. Mordstein, M., Kochs, G., Dumoutier, L., Renauld, J. C., Paludan, S. R., Klucher, K., and Staeheli, P. (2008) Interferonlambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4, e1000151
33. Bartlett, N. W., Buttigieg, K., Kotenko, S. V., and Smith, G. L. (2005) Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 86, 1589-1596
34. Mann, B. A., Huang, J. H., Li, P., Chang, H. C., Slee, R. B., O'Sullivan, A., Anita, M., Yeh, N., Klemsz, M. J., Brutkiewicz, R. R., Blum, J. S., and Kaplan, M. H. (2008) Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J. Interferon Cytokine Res. 28, 367-380
35. Deonarain, R., Alcami, A., Alexiou, M., Dallman, M. J., Gewert, D. R., and Porter, A. C. (2000) Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J. Virol. 74, 3404-3409
36. Rosengard, A. M., Liu, Y., Nie, Z., and Jimenez, R. (2002) Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. U. S. A. 99, 8808-8813
37. Yadav, V. N., Pyaram, K., Mullick, J., and Sahu, A. (2008) Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J. Virol. 82, 3283-3294
38. Esteban, D. J., Nuara, A. A., and Buller, R. M. (2004) Interleukin-18 and glycosaminoglycan binding by a protein encoded by variola virus. J. Virol. 85, 1291-1299
39. Alejo, A., Ruiz-Arguello, M. B., Ho, Y., Smith, V. P., Saraiva, M., and Alcami, A. (2006) A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc. Natl. Acad. Sci. U. S. A. 103, 5995-6000
40. Brunetti, C. R., Paulose-Murphy, M., Singh, R., Qin, J., Barrett, J. W., Tardivel, A., Schneider, P., Essani, K., and McFadden, G. (2003) A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc. Natl. Acad. Sci. U. S. A. 100, 4831-4836
41. Earl, P. L., Americo, J. L., Wyatt, L. S., Eller, L. A., Whitbeck, J. C., Cohen, G. H., Eisenberg, R. J., Hartmann, C. J., Jackson, D. L., Kulesh, D. A., Martinez, M. J., Miller, D. M., Mucker, E. M., Shamblin, J. D., Zwiers, S. H., Huggins, J. W., Jahrling, P. B., and Moss, B. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182-185
42. Earl, P. L., Americo, J. L., Wyatt, L. S., Espenshade, O., Bassler, J., Gong, K., Lin, S., Peters, E., Rhodes, L., Jr., Spano, Y. E., Silvera, P. M., and Moss, B. (2008) Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 105, 10889-10894
43. Kim, M., Yang, H., Kim, S. K., Reche, P. A., Tirabassi, R. S., Hussey, R. E., Chishti, Y., Rheinwald, J. G., Morehead, T. J., Zech, T., Damon, I. K., Welsh, R. M., and Reinherz, E. L. (2004) Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279, 25838-25848
44. Waibler, Z., Anzaghe, M., Frenz, T., Schwantes, A., Pohlmann, C., Ludwig, H., Palomo-Otero, M., Alcami, A., Sutter, G., and Kalinke, U. (2009) Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83, 1563-1571
45. Jacobs, B. L., Langland, J. O., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S. A., Wong, S., Huynh, T., and Baskin, C. R. (2009) Vaccinia virus vaccines: past, present and future. Antiviral Res. 84, 1-13